Get the Stockscreener App
1.12
0.00%
0.00
After Hours:
1.11
-0.01
-0.89%
Longeveron Inc stock is traded at $1.12, with a volume of 838.87K.
It is up +0.00% in the last 24 hours and up +15.05% over the past month.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
See More
Previous Close:
$1.12
Open:
$1.1
24h Volume:
838.87K
Relative Volume:
0.16
Market Cap:
$32.79M
Revenue:
$1.20M
Net Income/Loss:
$-22.70M
P/E Ratio:
-0.8612
EPS:
-1.3005
Net Cash Flow:
$-19.24M
1W Performance:
-0.88%
1M Performance:
+15.05%
6M Performance:
+34.29%
1Y Performance:
-23.29%
1-Day Range:
$1.07
$1.14
1-Week Range:
$1.07
$1.18
52-Week Range:
$0.475
$1.83
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
1.12 | 32.79M | 1.20M | -22.70M | -19.24M | -1.3005 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Longeveron Restores Executive Pay After Recent Financing - TipRanks
LGVN Stock Price, Quote & Chart | LONGEVERON INC-A (NASDAQ:LGVN) - ChartMill
Longeveron Inc. Files Form 8-K Current Report with SEC – Company Details and Stock Information (2026) - Minichart
Aug Setups: Is Longeveron Inc stock a value trapMarket Growth Summary & Safe Capital Allocation Plans - baoquankhu1.vn
Longeveron restores executive pay, approves new stock unit grants following financing By Investing.com - Investing.com South Africa
Longeveron restores executive pay, approves new stock unit grants following financing - Investing.com
Longeveron IncRepaid Executives For Compensation Reductions Following FinancingSEC Filing - TradingView — Track All Markets
Longeveron grants RSUs to executives after restoring reduced pay - TradingView — Track All Markets
Longeveron (NASDAQ: LGVN) restores pay and grants RSUs after financing - Stock Titan
Longeveron Prospectus Filed For Resale Of Up To 30.9 Million Class A Common Shares By Selling Stockholders- SEC Filing - TradingView — Track All Markets
Longeveron (NASDAQ: LGVN) resale filing details 30.9M registered shares - Stock Titan
Biotechs Racing to Translate Longevity Science Into Real Therapies — And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - Cantech Letter
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - Benzinga
IPO Launch: What is Longeveron Incs book value per share2026 Earnings Impact & Weekly Chart Analysis and Guides - baoquankhu1.vn
Longeveron receives China patent for stem cell potency assay By Investing.com - Investing.com Canada
Longeveron receives China patent for stem cell potency assay - Investing.com
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - The Manila Times
China grants Longeveron stem cell patent rights running through 2041 - Stock Titan
Risk Check: Is Longeveron Inc stock good for income investors2026 Summary & Verified Short-Term Plans - baoquankhu1.vn
Market Outlook: Whats Longeveron Incs historical return2026 Opening Moves & Weekly High Return Opportunities - baoquankhu1.vn
Investment Review: Is Longeveron Inc exposed to currency risksEarnings Trend Report & Step-by-Step Trade Execution Guides - baoquankhu1.vn
LGVN Technical Analysis & Stock Price Forecast - Intellectia AI
[Form 4] Longeveron Inc. Insider Trading Activity - Stock Titan
Longeveron (LGVN) CMO has shares withheld to cover RSU tax obligations - Stock Titan
Longeveron (LGVN) CFO has 13,145 shares withheld to cover RSU tax - Stock Titan
Longeveron (LGVN) CEO has shares withheld to cover RSU tax bill - Stock Titan
Longeveron (NASDAQ: LGVN) CTO reports RSU tax-withholding of 8,633 shares - Stock Titan
Patterns Watch: Can Longeveron Inc outperform in the next rallyEarnings Recap Summary & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
LGVN Stock Chart | LONGEVERON INC-A (NASDAQ:LGVN) - ChartMill
LGVN: Laromestrocel shows strong clinical progress and regulatory momentum across multiple indications - TradingView
Movement Recap: How cyclical is Longeveron Incs revenue stream2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Is Longeveron Inc stock good for income investorsTrade Entry Summary & Target Return Focused Picks - baoquankhu1.vn
Moving Averages: Will Longeveron Inc stock hit new highs in YEAR2026 Rallies & Step-by-Step Trade Execution Guides - baoquankhu1.vn
(LGVN.O) | Stock Price & Latest News - Reuters
Profit Review: Can Longeveron Inc outperform in the next rally2026 Major Catalysts & Reliable Price Breakout Alerts - baoquankhu1.vn
Longeveron Receives Extended Nasdaq Compliance Grace Period - tipranks.com
Longeveron Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Longeveron (NASDAQ: LGVN) granted more time to cure Nasdaq $1 bid rule - Stock Titan
Longeveron braces for Q4 results following recent funding boost - MSN
Longeveron Cancels Special Meeting, Reschedules Reverse Split Vote - TipRanks
Longeveron (NASDAQ: LGVN) shifts reverse split proposal to annual - Stock Titan
Longeveron Inc. (NASDAQ:LGVN) Q4 2025 earnings call transcript - MSN
Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN
Longeveron secures $15M financing with potential for additional $15M tied to trial milestones - MSN
If You Invested $1,000 in Longeveron Inc (LGVN) - Stock Titan
Returns Recap: What are Eureka Acquisition Corps earnings expectationsMarket Trend Report & Safe Entry Point Identification - baoquankhu1.vn
Aug Action: What is Longeveron Incs revenue forecastTrade Volume Report & Weekly Breakout Stock Alerts - baoquankhu1.vn
Experience real-time quotes, in-depth charts, and analyst ratings - webull.com
Longeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call Transcript - Insider Monkey
Longeveron's third-quarter 2026 HLHS trial outcomes may confirm the viability of its overall business approach—while its Alzheimer's program continues to divert focus - Bitget
Longeveron’s Alzheimer’s Program Faces High Late-Stage Failure Risk and Potential Pipeline Pressure - TipRanks
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):